Table 2.
Comparison on the Baseline Characteristic of Tumor Control Group and Progressive Disease Group [n (%)]
| Characteristics | Tumor control | Progressive disease | P-value |
|---|---|---|---|
| (PR+SD) | (PD) | (Fisher’s exact test) | |
| n= 19 | n= 7 | ||
| Gender | |||
| Male | 7 (77.8) | 2 (22.2) | 1.000 |
| Female | 12 (70.6) | 5 (29.4) | |
| Age (year) | |||
| Median (range) | |||
| < 65 Year | 10 (71.4) | 4 (28.6) | 1.000 |
| ≥ 65 Year | 9 (75.0) | 3 (25.0) | |
| Extent of disease | |||
| Locally advanced | 4 (57.1) | 3 (42.9) | 0.290* |
| Metastatic | 12 (85.7) | 2 (14.3) | |
| Mixed | 3 (60.0) | 2 (40.0) | |
| Primary tumor site | |||
| Cholangiocarcinoma | 16 (72.7) | 6 (27.3) | 1.000 |
| Gallbladder | 3 (75.0) | 1 (25.0) | |
| Performance status (ECOG) | |||
| 0 | 3 (75.0) | 1 (25.0) | 0.817* |
| 1 | 15 (71.4) | 6 (28.6) | |
| 2 | 1 (100.0) | 0 (0.0) | |
| Chemotherapeutic Regimens | |||
| Gemcitabine/Cisplatin | 13 (65.0) | 7 (35.0) | 0.146 |
| Gemcitabine/Carboplatin | 6 (100.0) | 0 (0.0) |
*
-Chi-square test